George Dranitsaris

Summary

Affiliation: University of Toronto

Publications

  1. doi A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe
    George Dranitsaris
    Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
    J Oncol Pharm Pract 18:57-67. 2012
  2. doi The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs
    George Dranitsaris
    Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
    J Eval Clin Pract 18:343-51. 2012
  3. pmc External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Canada
    BMC Cancer 7:110. 2007
  4. ncbi The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines
    George Dranitsaris
    Breast Cancer Res Treat 107:443-50. 2008
  5. ncbi Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model
    George Dranitsaris
    Toronto Sunnybrook Regional Cancer Centre, Ontario, Canada
    Lancet Oncol 6:856-63. 2005
  6. ncbi Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature
    George Dranitsaris
    Cancer Care Ontario, 429 Danforth Ave, Suite 476, Toronto, Canada, M4K 1P1
    J Oncol Pharm Pract 11:69-78. 2005
  7. doi nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial
    George Dranitsaris
    Breast Cancer Res Treat 119:717-24. 2010
  8. doi Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer
    George Dranitsaris
    Princess Margaret Hospital, Humber River Regional Cancer Centre, Toronto, Canada
    J Oncol Pharm Pract 15:67-78. 2009
  9. ncbi Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool
    George Dranitsaris
    British Columbia Cancer Agency, Humber River Regional Cancer Centre, Toronto, Ontario, Canada
    Clin Colorectal Cancer 6:367-73. 2007
  10. doi Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model
    George Dranitsaris
    Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
    Am J Clin Oncol 31:369-74. 2008

Detail Information

Publications59

  1. doi A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe
    George Dranitsaris
    Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
    J Oncol Pharm Pract 18:57-67. 2012
    ..4-month survival benefit to patients with metastatic colorectal cancer (mCRC). The threshold used for economic value was three times the Spanish per capita GDP, as recommended by the World Health Organization (WHO)...
  2. doi The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs
    George Dranitsaris
    Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
    J Eval Clin Pract 18:343-51. 2012
    ..4-month survival benefit to patients with metastatic colorectal cancer (mCRC)...
  3. pmc External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Canada
    BMC Cancer 7:110. 2007
    ..In this paper we review external factors that may influence decision-making bodies and present a case study of media response in Ontario, Canada to adjuvant trastuzumab for breast cancer...
  4. ncbi The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines
    George Dranitsaris
    Breast Cancer Res Treat 107:443-50. 2008
    ....
  5. ncbi Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model
    George Dranitsaris
    Toronto Sunnybrook Regional Cancer Centre, Ontario, Canada
    Lancet Oncol 6:856-63. 2005
    ..We aimed to develop a prediction model for anaemia in patients with breast cancer who were receiving adjuvant chemotherapy...
  6. ncbi Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature
    George Dranitsaris
    Cancer Care Ontario, 429 Danforth Ave, Suite 476, Toronto, Canada, M4K 1P1
    J Oncol Pharm Pract 11:69-78. 2005
    ..A systematic review and meta-analysis was conducted to test the hypothesis that oncology health care workers are at an increased risk of cancer, reproductive complications and acute toxic events...
  7. doi nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial
    George Dranitsaris
    Breast Cancer Res Treat 119:717-24. 2010
    ..Given its improved safety profile, potentially enhanced efficacy and comparable economic impact, nab-paclitaxel (weekly or q3w) can be considered a reasonable alternative to docetaxel as first-line chemotherapy for MBC...
  8. doi Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer
    George Dranitsaris
    Princess Margaret Hospital, Humber River Regional Cancer Centre, Toronto, Canada
    J Oncol Pharm Pract 15:67-78. 2009
    ..To provide health economic data for the Canadian setting, an economic analysis comparing each of nab-paclitaxel and docetaxel, both as alternatives to paclitaxel in metastatic breast cancer was conducted...
  9. ncbi Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool
    George Dranitsaris
    British Columbia Cancer Agency, Humber River Regional Cancer Centre, Toronto, Ontario, Canada
    Clin Colorectal Cancer 6:367-73. 2007
    ..However, both are associated with severe diarrhea, leading to hospitalization, dose reductions/delays, and even death. In this study, the development of a prediction model for severe diarrhea is described...
  10. doi Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model
    George Dranitsaris
    Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
    Am J Clin Oncol 31:369-74. 2008
    ..To develop a cycle-based risk prediction model for neutropenic complications (NC) during chemotherapy with doxorubicin (DOX) or a pegylated liposomal formulation (PLD) for patients with metastatic breast cancer (MBC)...
  11. doi The development of a value based pricing index for new drugs in metastatic colorectal cancer
    George Dranitsaris
    Faculty of Health Sciences, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
    Eur J Cancer 47:1299-304. 2011
    ..We developed a global pricing index for new cancer drugs in patients with metastatic colorectal cancer (mCRC) that encompasses all of these attributes...
  12. ncbi Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis
    George Dranitsaris
    Cancer Care Ontario, 429 Danforth Ave, Suite 476, Toronto M4K 1P1, Canada
    Support Care Cancer 13:318-24. 2005
    ..In this study, a cost of illness analysis was conducted to estimate the overall economic impact of grade III/IV diarrhea in patients with colorectal cancer receiving adjuvant or palliative chemotherapy...
  13. ncbi Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen
    George Dranitsaris
    Ontario Cancer Institute Princess Margaret Hospital, Ottawa Regional Cancer Centre and Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    Am J Clin Oncol 26:289-96. 2003
    ..However, when efficacy and cost effectiveness are considered together, letrozole could be preferentially considered...
  14. doi Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis
    George Dranitsaris
    Princess Margaret Hospital, Toronto, ON, Canada
    Support Care Cancer 19:1807-13. 2011
    ..001). In the current study, a cost effectiveness analysis was conducted to estimate the economic value of posaconazole as an alternative to Flu/Itra when used to prevent IFI in this patient population...
  15. ncbi Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea
    George Dranitsaris
    Cancer Care Ontario, 429 Danforth Avenue, Toronto, Ontario M4K 1P1, Canada
    Can J Gastroenterol 19:83-7. 2005
    ..In the present study, a cost of illness analysis was conducted to estimate the overall cost of patients with colorectal cancer who were hospitalized for supportive care secondary to severe diarrhea...
  16. doi Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value
    George Dranitsaris
    Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
    Int J Technol Assess Health Care 27:23-30. 2011
    ....
  17. doi Advances in cancer therapeutics and patient access to new drugs
    George Dranitsaris
    Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
    Pharmacoeconomics 29:213-24. 2011
    ..Current strategies used by many countries around the world to manage cancer drug budgets are presented, along with a proposed approach using pharmacoeconomic methodology that may increase patient access...
  18. ncbi The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy
    Mark Vincent
    London Regional Cancer Program, 790 Commissioners Road E, London, ON, N6A 4L6, Canada
    Support Care Cancer 15:265-72. 2007
    ..e., a hemoglobin (Hb) of <or=100 g/l] in patients with advanced nonsmall cell lung cancer (NSCLC) receiving palliative chemotherapy is described...
  19. ncbi Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients
    Orit Freedman
    Division of Medical Oncology, Princess Margaret Hospital, Suite 5 205, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Breast Cancer Res Treat 118:377-83. 2009
    ..70 (95% CI 0.60-0.80). This model was able to identify risk information that could be helpful in assessing which patients would most likely benefit from fulvestrant as an intervention with the objective being a delay in chemotherapy...
  20. ncbi Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane
    Sunil Verma
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Am J Clin Oncol 30:297-302. 2007
    ..Common therapeutic alternatives include capecitabine and vinorelbine. This retrospective chart review compares overall survival following treatment with capecitabine, vinorelbine, or both agents sequentially in this group of women...
  21. doi A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases
    Eitan Amir
    Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer 116:284-91. 2010
    ..This study therefore aimed to assess the effect of this dose of vitamin D(3) in patients with bone metastases from breast cancer...
  22. doi Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, Ontario, Canada
    Am J Cardiovasc Drugs 9:45-58. 2009
    ....
  23. doi Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer
    Eitan Amir
    Division of Medical Oncology and Hematology, University of Toronto and Princess Margaret Hospital Ambulatory Care, Princess Margaret Hospital Toronto General Research Institute, University of Toronto and University Health Network Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Toronto Department of Medical Oncology, R S McLaughlin Durham Regional Cancer Centre, Oshawa Division of Medical Oncology, University of Ottawa and The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    Am J Clin Oncol 36:436-42. 2013
    ..This study assessed the feasibility of conducting a randomized trial of less frequent bisphosphonate administration in women with breast cancer and low-risk bone metastases...
  24. doi Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design
    Farrah Kassam
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Breast Cancer 9:29-33. 2009
    ..This has implications for clinical practice and trial design. We evaluated the duration of first-, second-, and third-line chemotherapy as a surrogate for duration of treatment response...
  25. ncbi Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study
    Christopher M Booth
    Toronto Sunnybrook Regional Cancer Centre and Princess Margaret Hospital, Toronto, Canada
    J Support Oncol 5:374-80. 2007
    ..Several patient characteristics that predict which patients are at increased risk of developing severe symptoms were identified...
  26. ncbi The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer
    George Dranitsaris
    Consultant Pharmacist, Cancer Care Ontario, Ontario M5G 2L7, Canada
    J Eval Clin Pract 11:350-6. 2005
    ..A provincial drug database was used to determine the impact that these new policies had on the rate of vinorelbine and gemcitabine uptake within the CCO new drug funding programme...
  27. pmc The use of complementary and alternative medicines among patients with locally advanced breast cancer--a descriptive study
    Lucy K Helyer
    Department of Surgical Oncology, Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada
    BMC Cancer 6:39. 2006
    ..Complementary and alternative medicine (CAM) use is common among cancer patients. This paper reviews the use of CAM in a series of patients with locally advanced breast cancer (LABC)...
  28. ncbi A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy
    Mark Clemons
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 108:79-85. 2008
    ..We evaluated the impact of second-line ibandronate on pain control and markers of bone turnover in these patients...
  29. ncbi Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain
    Reuben Broom
    Division of Medical Oncology, Princess Margaret Hospital, Ontario, Canada
    J Pain Symptom Manage 38:244-57. 2009
    ..87) and treatment experience (alpha's=0.89-0.92). The FACT-BP scale is meaningful and appears appropriate for broader use. The assessment of satisfaction (FACIT-TS-BTCSQ) raised questions that will require further research...
  30. doi Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer
    Sheray N Chin
    Division of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Canada and Department of Medicine, University of Toronto, Canada
    Clin Breast Cancer 9:108-17. 2009
    ..As there are inherent reporting biases associated with clinical trials, we sought to assess the prevalence, severity, and effect of urogenital side effects of endocrine therapy in the non-trial setting...
  31. ncbi Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists
    Sunil Verma
    Toronto Sunnybrook Regional Cancer Centre and Cancer Care Ontario, Toronto, Canada
    Support Care Cancer 12:852-8. 2004
    ..A questionnaire was therefore developed and administered to determine how medical oncologists in Canada use BPs in clinical practice...
  32. ncbi Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy
    Mark J Clemons
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 24:4895-900. 2006
    ....
  33. ncbi Does prolonging the time to testicular cancer surgery impact long-term cancer control: a systematic review of the literature
    David Bell
    Dalhousie University, Halifax, Nova Scotia, Canada
    Can J Urol 13:30-6. 2006
    ..e. recurrence free survival, overall survival)?..
  34. ncbi Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, Ontario, Canada
    Pharmacoeconomics 24:593-607. 2006
    ..002). A Canadian pharmacoeconomic analysis was conducted to measure the economic value of dalteparin for this indication...
  35. ncbi Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer
    Christine Simmons
    Division of Medical Oncology Sunnybrook Health Sciences Centre Odette Cancer Centre Toronto, Ontario, Canada
    Anticancer Res 29:2707-11. 2009
    ..The effects of this long-term BP use on calcium metabolism in MBC patients have not previously been described...
  36. ncbi Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, Ontario, Canada
    Pharmacoeconomics 22:375-87. 2004
    ..Whilst paclitaxel is associated with less haematological toxicity, such as febrile neutropenia and anaemia, docetaxel causes less sensory and motor neuropathy...
  37. ncbi Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer
    Mark Clemons
    Division of Medical Oncology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N3M5, Canada
    Oncologist 11:227-33. 2006
    ..This paper reviews the current efficacy measures used in recent bisphosphonate trials and discusses their benefits and limitations. It also explores the role of bone biomarkers and their potential use in monitoring treatment response...
  38. doi Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia
    James A Chiarotto
    Department of Medicine, Oncology Program, Rouge Valley Health System, 2863 Ellesmere Road, Toronto, Ontario, M1E 5E9, Canada
    Support Care Cancer 21:2727-31. 2013
    ..patients with early stage breast cancer (ESBC) regardless of the day-before absolute neutrophil count (ANC) lead to an increased incidence of chemotherapy-induced febrile neutropenia (CIFN)? What factors may predispose patients to CIFN?..
  39. pmc Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia
    George Dranitsaris
    Department of Pharmacy, Nelson Mandela Metropolitan University, PO Box 77000, Port Elizabeth, 6031, South Africa
    Malays J Med Sci 18:32-43. 2011
    ..4-month survival benefit in patients with metastatic colorectal cancer (mCRC)...
  40. doi Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer
    Eitan Amir
    Division of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Clin Oncol 30:587-92. 2012
    ..This prospective study investigated receptor status of primary tumors and metastases in the same patient and assessed the impact of discordance on patient management and survival...
  41. ncbi Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer
    George Dranitsaris
    Cancer Care Ontario, Toronto, Canada
    Curr Opin Oncol 14:375-83. 2002
    ..This article reviews the pharmacoeconomic literature to provide guidance on the cost-effective use of chemotherapy in the treatment of advanced nonsmall-cell lung cancer...
  42. pmc Recent developments in bisphosphonates for patients with metastatic breast cancer
    Mary C Gainford
    Division of Medical Oncology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5
    BMJ 330:769-73. 2005
  43. ncbi Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, Ontario, Canada
    Am J Cardiovasc Drugs 4:325-33. 2004
    ....
  44. ncbi Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, Ontario, Canada
    Appl Health Econ Health Policy 7:43-59. 2009
    ..To provide health economic data on the multiple oral PAH therapies currently available, a population-based cost-minimization analysis (CMA) was conducted for Canada...
  45. ncbi Does prolonging the time to renal cancer surgery affect long-term cancer control: a systematic review of the literature
    Michael Jewett
    University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    Can J Urol 13:54-61. 2006
    ..e., recurrence-free survival, overall survival)?..
  46. ncbi Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death
    Eileen Rakovitch
    Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Ontario, Toronto, Canada, M4N 3M5
    Breast Cancer Res Treat 90:139-48. 2005
    ..The objective of this study is to assess the presence of anxiety and depression in breast cancer patients who use CAM and assess how they perceive their risks of recurrence and dying from breast cancer compared to non-users...
  47. ncbi Do physicians follow systemic treatment and funding policy guidelines?
    Mark Clemons
    Toronto Sunnybrook Regional Cancer Centre, Canada
    Can J Clin Pharmacol 11:e168-78. 2004
    ..In addition we assessed whether or not physicians at these centres are following their local treatment guidelines and funding policies...
  48. ncbi Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy
    George Dranitsaris
    Cancer Care Ontario, Toronto, Canada
    Int J Technol Assess Health Care 20:289-95. 2004
    ....
  49. ncbi Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonate therapy in patients with metastatic breast cancer
    Christine Simmons
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Support Cancer Ther 4:182-7. 2007
    ..Herein, we review this new role of collagen N-telopeptide as a predictor of bone involvement and response to treatment, and of the palliative benefit of bisphosphonate therapy in patients with metastatic breast cancer...
  50. pmc A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
    Christina L Addison
    Division of Medical Oncology, Ottawa Hospital Cancer Centre, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
    Breast Cancer Res Treat 144:615-24. 2014
    ..Larger trials are required to assess the roles of biomarkers as predictors of adequacy of de-escalated therapy...
  51. doi Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, Canada
    Clin Appl Thromb Hemost 18:233-42. 2012
    ..In this evaluation, indirect statistical techniques were used to compare safety and efficacy between dalteparin and enoxaparin in these 2 high-risk patient populations...
  52. doi Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, ON, Canada
    Drugs 71:1527-36. 2011
    ..We also highlight issues of ongoing debate amongst key stakeholders and examine some of the commercial challenges faced by developers of biosimilars. As the leader of biosimilars drug approval and product uptake, the EU is highlighted...
  53. ncbi The price function of toxicity
    Mark D Vincent
    Department of Medical Oncology, London Regional Cancer Program, London, Ontario, Canada
    Lancet Oncol 10:299-303. 2009
    ....
  54. ncbi Surgical wait times for patients with urological cancers: a survey of Canadian surgeons
    Neil Fleshner
    University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    Can J Urol 13:3-13. 2006
    ..To obtain such data, a survey of Canadian urological surgeons was undertaken...
  55. ncbi The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant
    Aaron D Schimmer
    ABMT Long term Follow up Research Unit, Princess Margaret Hospital, University of Toronto, ABMT Program, Canada
    Support Care Cancer 10:247-52. 2002
    ..In conclusion, we present an inexpensive model of care for ABMT survivors that can be extended to adult survivors of malignancy not treated by ABMT...
  56. ncbi What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?
    Sunil Verma
    J Clin Oncol 23:6260; author reply 6261. 2005
  57. ncbi Systemic treatment of bone metastases from breast cancer: is it all that it's cracked up to be?
    Mary C Gainford
    J Clin Oncol 23:4802-3; author reply 4803. 2005
  58. ncbi Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature
    Fred Saad
    University of Montreal, CHUM, Hopital Notre Dame, Montreal, Quebec, Canada
    Can J Urol 13:16-24. 2006
    ..Is there a known association between duration of wait time beyond the recommended standard and clinical outcome (i.e. recurrence free survival, overall survival)?..
  59. ncbi Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature
    Yves Fradet
    Laval University, CHUQ Hôtel Dieu de Québec City, Quebec, Canada
    Can J Urol 13:37-47. 2006
    ..e., recurrence-free survival, overall survival)?..